


Pipeline Therapies for Parkinson's Disease

Melissa Houser, M.D.
Scripps Clinic



Clinical trials 101

- How do we categorize trials?
 - Symptomatic treatment vs disease modifying
 - Mechanism of action of a compound
 - Phase studies
 - phase 1 safety
 - Phase 2 efficacy
 - Phase 3 long term large study**

Two Main Types of Therapy

- Knee pain analogy




- **Symptomatic therapy:** regardless of cause, Tylenol or ibuprofen helps
- **Disease modifying therapy:** fix the source of the pain (arthritis, torn meniscus) stops further deterioration of that knee

Symptomatic

- Changing brain chemical transporters
 - Dopamine
 - Serotonin
 - Acetylcholine/glutamate
- Changing brain functional network
 - Deep Brain Stimulation
 - MRIfUS

Disease modifying

An altered trajectory for Parkinson's



Mechanism of Action

- *Antioxidants* – reducing oxidative stress
- *Botanicals* – herbal extracts
- *Cell therapy* – cell transplantation or peripheral delivery of cells.
- *Dopaminergic symptom relief* – agents that mimic the chemical dopamine.
- *Energy and mitochondria* – restoring mitochondrial function.
- *GBA* – enhancing the activity of glucocerebrosidase.
- *GLP-1 agonists* – a class of diabetes drugs.
- *Immunotherapy* – antibody-based agents.

Mechanism of Action


- *Kinase inhibitors* – blocking certain kinase activity.
- *Microbiome/GIT* – focused on the gastrointestinal tract.
- *Neurotrophic factors* – delivery of GDNF or CDFN.
- *Non-dopaminergic symptom relief* – symptomatic therapies not involving dopamine.
- *Targeting alpha synuclein* – agents inhibiting alpha synuclein aggregation.
- *Other* – where there was only one treatment for a specific MOA.

THE PIPELINE

Disease Modifying Therapies


Therapy Categories

- Targeting aSN
- Immunotherapy
- Microbiome/GIT
- DA symptomatic
- GBA
- Kinase inhib.
- Non-DA symp.
- Neurotrophic
- Botanicals
- Cell therapy
- Energy/mitoch.
- GLP-1 agonist
- Antioxidants
- Other



Symptomatic Therapies

Disease Modifying Therapies



Symptomatic Therapies

repurposed/refashioned



KYNMOBI™
 (apomorphine HCl) sublingual film
 10 mg • 15 mg • 20 mg • 25 mg • 30 mg

ts (34% of trials)

ONCE DAILY AT BEDTIME

GOCOVRI®
 (amantadine) extended release capsules
 68.5 mg | 137 mg

Bypasses the stomach



Delivered in the intestine, where levodopa is mostly absorbed



Ongentys®
 (opicapone) capsules

Diabetes Drug Exenatide
 For Parkinson's Disease




Weekly dose of exenatide improves motor abilities

Exenatide can be used to treat immobility in Parkinson's disease




Honorable mention




- DBS technology
- Drugs that bypass the gut
- Alpha synuclein drugs
- Ultrasound therapy
- Stem cells
- Transdifferentiation

Get it in somehow!



Non-Oral Therapies




Levodopa
delivery

- patch/pump





- Accordian
pill





Lewy Bodies = alpha synuclein

Lewy
Body
Disease




Parkinson's
Disease

clumps of “toxic” alpha synuclein





Toxic


- destroy the cell
- interferes with synapse
- can spread out of cell and injure other cells (prion-like)
- inhibits axonal transport



Some ASN busters


- Prothena/Roche 
- Biogen 
- Proclara
- Modag
- Prasinezumab
- AstraZeneca/Takeda – (MEDI1341)
- AFFiRis _ vaccine ASN

MRIgfUS (ultrasound ablation)



Magnetic Stimulation

- Not electroconvulsive
- It's a magnetic device
- 8 positive, 6 neg trials
- OCD, depression, almost PTSD




“Stem Cell” Therapy



Embryonic stem cells



Induced pluripotent stem cells




In vitro differentiation into dopaminergic neural progenitors

Grafting into patient striatum








In vivo maturation into dopaminergic neurons

Patient derived stem cells




Evolution of Patient Stem Cells







Stem cell “tourism”



Xiang-Dong Fu, Phd, UCSD

One-Time Treatment Generates New Neurons,
Eliminates Parkinson's Disease in Mice

Inhibiting a single gene converts many cell types directly into dopamine-producing neurons



Unmet needs

- A drug that slows or stops the disease
- Non motor symptoms
 - Sexual
 - Sleep
 - Psychiatric
 - Autonomic
 - Cognitive

Resources

YOUR DOCTOR



Thanks! Empowerment for Parkinson's

The Parkinson's Association of San Diego
Invites You to a Day Not to Be Missed!



Wednesday, December 1, 2021
7:45 AM - Registration Opens
8:45 AM - 3:45 PM - Program

Marina Village Conference Center
1936 Quivira Way
San Diego, CA 92109

Come for a fun day of
learning, sharing and
empowering yourself
and each other.

Cost: \$20 per person
Includes light breakfast and
lunch. Scholarships available!

**Your safety matters.
Proof of vaccination
required upon check-in.
We ask participants to
follow CDC, state, and local mask
guidelines at the time of the event.**

Register now, space is limited!

- **By Phone:** 858-215-2570
- **By Mail:** Complete the registration form on the back of this flyer.
- **Online:** parkinsonsassociation.org



Sponsored by
ACADIA Pharmaceuticals, Inc.

SEE FULL AGENDA
ONLINE AT

PARKINSONSASSOCIATION.ORG

LIVE YOUR
BEST LIFE WITH
PARKINSON'S

GET
MOVING

COMMUNITY
RESOURCES
EXPLORE
NEW TOPICS

CAREGIVER
SUPPORT

EXHIBITOR
RESOURCE
FAIR



EMPOWER : MIND : BODY : SOUL

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease

Jeffrey S. Schweitzer, M.D., Ph.D., Bin Song, M.D., Ph.D., Todd M. Herrington, M.D., Ph.D., Tae-Yoon Park, Ph.D., Nayeon Lee, Ph.D., Sanghyeok Ko, Ph.D., Jaha Jeon, Ph.D., Young Cha, Ph.D., Kyungsang Kim, Ph.D., Quanzheng Li, Ph.D., Claire Henchcliffe, M.D., D.Phil., Michael Kaplitt, M.D., Ph.D., et al.

